BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 36809883)

  • 1. Oncolytic virus therapy for malignant gliomas: entering the new era.
    Fudaba H; Wakimoto H
    Expert Opin Biol Ther; 2023 Mar; 23(3):269-282. PubMed ID: 36809883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.
    Zeng J; Li X; Sander M; Zhang H; Yan G; Lin Y
    Front Immunol; 2021; 12():721830. PubMed ID: 34675919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic herpes simplex virus therapy for malignant glioma: current approaches to successful clinical application.
    Hua L; Wakimoto H
    Expert Opin Biol Ther; 2019 Aug; 19(8):845-854. PubMed ID: 31046478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic viruses as treatment for adult and pediatric high-grade gliomas: On the way to clinical success.
    Hervás-Corpión I; Alonso MM
    Int Rev Cell Mol Biol; 2023; 379():169-188. PubMed ID: 37541723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Achieving systemic delivery of oncolytic viruses.
    Hill C; Carlisle R
    Expert Opin Drug Deliv; 2019 Jun; 16(6):607-620. PubMed ID: 31144549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
    Russell L; Peng KW; Russell SJ; Diaz RM
    BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia.
    Wang W; Liu S; Dai P; Yang N; Wang Y; Giese RA; Merghoub T; Wolchok J; Deng L
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic Viruses for Malignant Glioma: On the Verge of Success?
    Suryawanshi YR; Schulze AJ
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OV Modulators of the Paediatric Brain TIME: Current Status, Combination Strategies, Limitations and Future Directions.
    Vazaios K; van Berkum RE; Calkoen FG; van der Lugt J; Hulleman E
    Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photodynamic augmentation of oncolytic virus therapy for central nervous system malignancies.
    Shimizu K; Kahramanian A; Jabbar MADA; Turna Demir F; Gokyer D; Uthamacumaran A; Rajan A; Saad MA; Gorham J; Wakimoto H; Martuza RL; Rabkin SD; Hasan T; Wakimoto H
    Cancer Lett; 2023 Sep; 572():216363. PubMed ID: 37619813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma.
    Barnard Z; Wakimoto H; Zaupa C; Patel AP; Klehm J; Martuza RL; Rabkin SD; Curry WT
    Neurosurgery; 2012 Sep; 71(3):741-8; discussion 748. PubMed ID: 22653387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gospel of malignant Glioma: Oncolytic virus therapy.
    Li J; Meng Q; Zhou X; Zhao H; Wang K; Niu H; Wang Y
    Gene; 2022 Apr; 818():146217. PubMed ID: 35093451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies.
    Heidbuechel JPW; Engeland CE
    J Hematol Oncol; 2021 Apr; 14(1):63. PubMed ID: 33863363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal timing of PD-1 blockade in combination with oncolytic virus therapy.
    Nguyen HM; Bommareddy PK; Silk AW; Saha D
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):971-980. PubMed ID: 34033895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus.
    Fujii K; Kurozumi K; Ichikawa T; Onishi M; Shimazu Y; Ishida J; Chiocca EA; Kaur B; Date I
    Cancer Gene Ther; 2013 Aug; 20(8):437-44. PubMed ID: 23827879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Oncolytic virotherapy in head and neck cancer].
    Runge A; Petersson M; Riechelmann H
    Laryngorhinootologie; 2022 Oct; 101(10):787-796. PubMed ID: 35977557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements.
    Yun CO; Hong J; Yoon AR
    Front Immunol; 2022; 13():953410. PubMed ID: 36091031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Oncolytic viruses for therapy of malignant glioma].
    Sosnovtceva AO; Grinenko NF; Lipatova AV; Chumakov PM; Chekhonin VP
    Biomed Khim; 2016 May; 62(4):376-90. PubMed ID: 27562991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zika Virus: A Neurotropic Warrior against High-Grade Gliomas-Unveiling Its Potential for Oncolytic Virotherapy.
    Calderón-Peláez MA; Maradei Anaya SJ; Bedoya-Rodríguez IJ; González-Ipuz KG; Vera-Palacios D; Buitrago IV; Castellanos JE; Velandia-Romero ML
    Viruses; 2024 Apr; 16(4):. PubMed ID: 38675903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas.
    Zhang Q; Liu F
    Cell Death Dis; 2020 Jun; 11(6):485. PubMed ID: 32587256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.